Comparison and Selection of Current Implantable Anti-Epileptic Devices

Research output: Contribution to journalArticle

Abstract

Implantable neural stimulators represent an advanced treatment adjunct to medication for pharmacoresistant epilepsy and alternative for patients that are not good candidates for resective surgery. Three treatment modalities are currently FDA-approved: vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation. These devices were originally trialed in very similar patient populations with focal epilepsy, but head-to-head comparison trials have not been performed. As such, device selection may be challenging due to large overlaps in clinical indications and efficacy. Here we will review the data reported in the original pivotal clinical trials as well as long-term experience with these technologies. We will highlight differences in their features and mechanisms of action which may help optimize device selection on a case-by-case basis.

Original languageEnglish (US)
Pages (from-to)369-380
Number of pages12
JournalNeurotherapeutics
Volume16
Issue number2
DOIs
StatePublished - Apr 15 2019

Fingerprint

Equipment and Supplies
Vagus Nerve Stimulation
Deep Brain Stimulation
Partial Epilepsy
Epilepsy
Clinical Trials
Technology
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Keywords

  • DBS
  • Neurostimulation
  • RNS
  • VNS
  • deep brain stimulation
  • epilepsy
  • responsive neurostimulation
  • seizures
  • vagus nerve stimulation

Cite this

@article{8057e102894d44498b46bd92f78f18c0,
title = "Comparison and Selection of Current Implantable Anti-Epileptic Devices",
abstract = "Implantable neural stimulators represent an advanced treatment adjunct to medication for pharmacoresistant epilepsy and alternative for patients that are not good candidates for resective surgery. Three treatment modalities are currently FDA-approved: vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation. These devices were originally trialed in very similar patient populations with focal epilepsy, but head-to-head comparison trials have not been performed. As such, device selection may be challenging due to large overlaps in clinical indications and efficacy. Here we will review the data reported in the original pivotal clinical trials as well as long-term experience with these technologies. We will highlight differences in their features and mechanisms of action which may help optimize device selection on a case-by-case basis.",
keywords = "DBS, Neurostimulation, RNS, VNS, deep brain stimulation, epilepsy, responsive neurostimulation, seizures, vagus nerve stimulation",
author = "Stephen Wong and Ram Mani and Shabbar Danish",
year = "2019",
month = "4",
day = "15",
doi = "10.1007/s13311-019-00727-2",
language = "English (US)",
volume = "16",
pages = "369--380",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "2",

}

Comparison and Selection of Current Implantable Anti-Epileptic Devices. / Wong, Stephen; Mani, Ram; Danish, Shabbar.

In: Neurotherapeutics, Vol. 16, No. 2, 15.04.2019, p. 369-380.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison and Selection of Current Implantable Anti-Epileptic Devices

AU - Wong, Stephen

AU - Mani, Ram

AU - Danish, Shabbar

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Implantable neural stimulators represent an advanced treatment adjunct to medication for pharmacoresistant epilepsy and alternative for patients that are not good candidates for resective surgery. Three treatment modalities are currently FDA-approved: vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation. These devices were originally trialed in very similar patient populations with focal epilepsy, but head-to-head comparison trials have not been performed. As such, device selection may be challenging due to large overlaps in clinical indications and efficacy. Here we will review the data reported in the original pivotal clinical trials as well as long-term experience with these technologies. We will highlight differences in their features and mechanisms of action which may help optimize device selection on a case-by-case basis.

AB - Implantable neural stimulators represent an advanced treatment adjunct to medication for pharmacoresistant epilepsy and alternative for patients that are not good candidates for resective surgery. Three treatment modalities are currently FDA-approved: vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation. These devices were originally trialed in very similar patient populations with focal epilepsy, but head-to-head comparison trials have not been performed. As such, device selection may be challenging due to large overlaps in clinical indications and efficacy. Here we will review the data reported in the original pivotal clinical trials as well as long-term experience with these technologies. We will highlight differences in their features and mechanisms of action which may help optimize device selection on a case-by-case basis.

KW - DBS

KW - Neurostimulation

KW - RNS

KW - VNS

KW - deep brain stimulation

KW - epilepsy

KW - responsive neurostimulation

KW - seizures

KW - vagus nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=85065481691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065481691&partnerID=8YFLogxK

U2 - 10.1007/s13311-019-00727-2

DO - 10.1007/s13311-019-00727-2

M3 - Article

AN - SCOPUS:85065481691

VL - 16

SP - 369

EP - 380

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 2

ER -